Recently, JumpCan Pharmaceutical received the Drug Registration Certificate (Certificate No.: 2023S01817) for Xiao'er Chiqiao Qingre Syrup, issued upon approval by the National Medical Products Administration (NMPA). This product is the first improved new traditional Chinese medicine (TCM) approved for market launch since the implementation of the new Provisions for Drug Registration, offering a new medication option for pediatric patients.
Xiao'er Chiqiao Qingre Syrup is categorized as a Class 2.2 new TCM drug. Developed by JumpCan Pharmaceutical to meet the differentiated medication needs of pediatric patients, it is an improved formulation based on the clinical advantages of the national medical insurance product Xiao'er Chiqiao Qingre Granules. By adopting new technologies and processes, the syrup optimizes the existing formula while retaining the original route of administration and indications.
The clinical efficacy of Xiao'er Chiqiao Qingre Syrup has been thoroughly validated through a stratified block randomized, double-blind, double-dummy, parallel-controlled, multi-center, non-inferiority clinical trial in pediatric patients, approved by the NMPA. The syrup formulation offers easier administration, improved taste, and enhanced drug absorption, significantly improving medication compliance in children.
As one of the listed pharmaceutical companies in China with the most extensive portfolio of pediatric varieties and formulations, JumpCan Pharmaceutical continues to deepen its layout in the advantageous pediatric field. Guided by clinical needs, the company is strengthening the secondary development of key marketed products, advancing the innovative R&D of new TCM drugs and high-end chemical drugs, to meet the differentiated medication needs of pediatric patients.
